



Premature termination of a Clinical Trial

Full title of the clinical Trial: An randomized, controlled, investigator-blinded, prospective, mono-centre study to evaluate the efficacy of fosfomycin versus meropenem in patients with complicated urinary tract infections

EudraCT Number: 2007-005112-37

Sponsor: Medical University of Vienna

Represented by (name): Graninger, Wolfgang, Univ.-Doz. DDr.

Reason for premature termination

of the clinical trial: Due to the strict inclusion and exclusion criteria, only 7 patients could be recruited in one year. Although fosfomycin was well tolerated by all patients, 2 of 3 patients developed an early relapse less than 20 days after the end of therapy. Therefore, it must be doubted that monotherapy with intravenous fosfomycin is an adequate treatment for patients with recurrent complicated urinary tract infections. For this reason, the study was terminated prematurely.

Study results (if available):

**Date and Signature of Sponsor
representative:**

30.05.2022